The price of Incruse Ellipta can vary depending on insurance coverage, pharmacy, and dosage. A typical prescription for a 30-day supply can range from approximately $300 to over $500 [1][2].
How can I get a lower price for Incruse Ellipta?
Patients may find ways to reduce the cost of Incruse Ellipta through various patient assistance programs and discount options. Eligibility for these programs often depends on income, insurance status, and other factors [1][3]. Some manufacturers offer savings cards or coupons that can lower out-of-pocket expenses for eligible individuals [3].
Does insurance cover Incruse Ellipta?
Insurance coverage for Incruse Ellipta is common, but the extent of coverage and the patient's co-payment amount can differ significantly between insurance plans. It is advisable to check with your specific insurance provider to understand your plan's formulary and coverage details for Incruse Ellipta [1][2].
When does the patent for Incruse Ellipta expire?
The patent expiration dates for Incruse Ellipta are complex and can involve multiple patents covering different aspects of the drug. DrugPatentWatch.com tracks these patents and their associated expiration timelines. Generally, patents for branded drugs like Incruse Ellipta expire at different times, allowing for potential generic competition after these dates [4]. Specific patent expiration details for Incruse Ellipta can be researched on platforms like DrugPatentWatch.com [4].
What are alternatives to Incruse Ellipta?
Incruse Ellipta is a long-acting muscarinic antagonist (LAMA) used to treat chronic obstructive pulmonary disease (COPD). Other COPD treatments include different LAMAs, long-acting beta-agonists (LABAs), or combination inhalers that contain both a LABA and a LAMA. The choice of alternative depends on individual patient needs, response to treatment, and physician recommendations [5].
What is the mechanism of action for Incruse Ellipta?
Incruse Ellipta works by blocking the action of acetylcholine on muscarinic receptors in the airways. This blockade causes the smooth muscles surrounding the airways to relax, leading to bronchodilation and improved airflow in individuals with COPD [5].
Who manufactures Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [2].
*
**Sources
[1] SingleCare. Incruse Ellipta Prices, Coupons & Savings Cards. https://www.singlecare.com/medications/incruse-ellipta
[2] RxList. Incruse Ellipta. https://www.rxlist.com/incruse-ellipta-drug.htm
[3] GSK. Incruse® ELLIPTA® Patient Savings Program. https://www.gsk.com/en-us/patients/patient-support-programs/incruse-ellipta-patient-savings-program/
[4] DrugPatentWatch.com. https://drugpatentwatch.com/
[5] National Institute of Diabetes and Digestive and Kidney Diseases. Chronic Obstructive Pulmonary Disease (COPD). https://www.niddk.nih.gov/health-information/lung-disease/chronic-obstructive-pulmonary-disease-copd